Please enable Javascript
CRPC
Metastatic castration-resistant prostate cancer
Advertisement
Androgen Signaling Combinations for mCRPC: Analyzing Ipilimumab Plus AAPA
Emily Menendez
CRPC
|
July 10, 2024
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
Read More
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
Vishnu Murthy
CRPC
|
July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
View More
Are Androgen Receptor Signaling Inhibitors Related to Cardiovascular Events in Advanced Prostate Cancer?
Katy Marshall
CRPC
|
June 21, 2024
The study’s primary end points were the incidence of all-grade or grade 3 and higher cardiovascular events.
Read More
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
View More
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
Oliver Sartor, MD
RLT
|
June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
View More
Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC
Geoffrey Johnson, MD, PhD
RLT
|
June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
View More
Enhancing Genetic Testing Rates in Metastatic Prostate Cancer: Trends, Challenges, and Opportunities
Pedro Barata, MD
CRPC
|
June 13, 2024
Dr. Pedro Barata discusses his research letter examining patterns of HRR mutation genetic testing in men with mCRPC.
View More
177Lu-PSMA-617 Boosts Antitumor Effects in Real-World Setting for mCRPC
Emily Menendez
Prostate Cancer
|
June 13, 2024
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Read More
Intensified RLT Boosts Treatment Efficacy in Patients With mCRPC
Emily Menendez
CRPC
|
June 13, 2024
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Read More
PSMAfore: Informing Future Trials of 177Lu-PSMA-617 Versus Chemotherapy for mCRPC
Karine Tawagi, MD
Advancements in Oncology
|
June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
View More
ARAMIS Follow-Up: PSA Levels, Radiological Progression in nmCRPC
Alicia Morgans, MD, MPH
CRPC
|
June 12, 2024
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
View More
PSMA Tandem Treatment Offers Benefit for Patients With mCRPC
Zachary Bessette
RLT
|
June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Read More
Promising Phase 3 Trial Results for [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
Brandon Twyford
CRPC
|
June 10, 2024
The PSMAfore trial shows [177Lu]Lu-PSMA-617 significantly improves rPFS, ORR, and PSA50 in taxane-naive patients with mCRPC.
Read More
Identifying Blood-Based Markers for Optimized Bipolar Androgen Therapy in mCRPC
Samuel Denmeade, MD
CRPC
|
June 6, 2024
Dr. Denmeade highlights his research on blood-based markers of differential efficacy of BAT and enzalutamide in TRANSFORMER.
View More
Prostate Cancer Management in Focus: Dr. Karine Tawagi’s Thoughts on 177Lu-PSMA-617
GU Oncology Now Editors
Advancements in Oncology
|
June 13, 2024
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
Read More
Impact of Concomitant Therapies on Survival Outcomes in Non-Metastatic CRPC
Soumyajit Roy, MD
CRPC
|
June 6, 2024
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
View More
NEPTUNES: Nivolumab, Ipilimumab for Metastatic Prostate Cancer With an Immunogenic Signature
Zachary Bessette
CRPC
|
June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Read More
Potential of ctDNA Burden as a Prognostic Biomarker for Efficacy in Patients With mCRPC
Katy Marshall
CRPC
|
June 3, 2024
Investigators quantified baseline and week 9 serial ctDNA samples through FoundationOneLiquid CDx.
Read More
First-In-Human Study Evaluating Safety of JNJ-6420 for mCRPC
Michael Morris, MD
RLT
|
June 4, 2024
Dr. Morris discusses a phase 1 study of JNJ-6420 for patients with mCRPC who received at least prior ARPI.
View More
CHAARTED2: Improving Outcomes in Patients With mCRPC
Christos Kyriakopoulos, MD
CRPC
|
June 4, 2024
Drs. Kyriakopoulos and Koshkin break down the CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group.
View More
Load More
Advertisement
Advertisement
Advertisement